Table 1.
Baseline characteristics by treatment group*
| Treatment Group | ||||
| Characteristics | Chloroquine | Amodiaquine | Sulphadoxine-Pyrimethamine | Artesunate-Amodiaquine |
| No. of patients enrolled | 320 | 385 | 383 | 346 |
| Ejeda | 51 | 51 | 50 | 50 |
| Ihosy | 62 | 62 | 61 | 63 |
| Miandrivazo | 67 | 69 | 69 | 68 |
| Maevatanana | 55 | 56 | 56 | 55 |
| Tsiroanomandidy | 43 | 48 | 48 | 0 |
| Moramanga | 42 | 39 | 40 | 40 |
| Andapa | 0 | 32 | 29 | 41 |
| Farafangana | 0 | 28 | 30 | 29 |
| Age | ||||
| median (range), y | 5 (0.5 – 15) | 5 (0.5 – 15) | 5 (0.5 – 15) | 5 (0.5 – 15) |
| Proportion of children ≤ 5 years | 142 (45.4) | 185 (48.7) | 182 (47.8) | 167 (48.7) |
| Weight, median (IQR), kg | 15 (6 – 58) | 15 (5 – 62) | 14 (6 – 60) | 13 (2.6 – 56) |
| Female | 158 (49.5) | 188 (48.8) | 186 (48.6) | 169 (49.0) |
| Temperature, mean (95% CI) | 38.4 (38.3 – 38.5) | 38.4 (38.3 – 38.5) | 38.4 (38.3 – 38.5) | 38.6 (38.5 – 38.7) |
| Trophozoite density, geometric mean (range), parasite/μl | 15,302 (1,241 – 200,000) |
133,068 (1,000 – 194,000) |
13,880 (1,000 – 196,000) |
14,346 (1669 – 192000) |
| Haemoglobin, median (IQR), g/dL | 10.1 (5.3 – 15.8) | 10.2 (5.8 – 15.6) | 10.0 (5.6 – 14.7) | 10.1 (5.1 – 14.5) |
| Anemic at enrollment± | 107 (39.3) | 114 (34.5) | 127 (38.5) | 103 (35.4) |
Abbreviations: CI, confidence interval; IQR, interquartile range.
*Data are presented as No. (%) unless otherwise indicated.
†Anaemia defined as haemoglobin of less than 10 g/dL.